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Changes in performance with prior feature selection 1
Random forest (RF) is designed to create uncorrelated trees using random subsets of 2
features in each node of each tree. RF by itself is a great tool for feature selection from 3
a high dimensional set of features. But we observed that the prediction accuracy is 4
improved when a prior feature selection (RELIEFF) [1] approach is implemented. Table 5
A shows the performance of RF, VMRF and CMRF with and without RELIEFF 6
feature selection in 2 drug sets of GDSC. 7
Table A: RF, VMRF, CMRF results (5 fold cross validation) with and without prior feature selection
With RELIEFF Without RELIEFF
Drug Set Common Target Drug Name RF VMRF CMRF RF VMRF CMRF
SC1 EGFR Erlotinib 0.5156 0.5193 0.5301 0.4093 0.4312 0.4384
Lapatinib 0.5544 0.5742 0.5699 0.4747 0.4722 0.4881
SC2 ABL1 AZD-0530 0.3553 0.3810 0.3990 0.1968 0.1919 0.2124
TAE-684 0.4060 0.4100 0.4338 0.2216 0.2692 0.2684
Performance Analysis for drugsets consisting of more 8
than two drugs 9
We have generated empirical copulas for the bivariate cases as they are able to capture 10
all forms of dependency structures. However, generation of empirical copulas has high 11
computational complexity along with the need for a significant number of training 12
samples at each node. Thus for more than two drug responses, we have considered 13
parametric copulas and the difference between Gaussian copula parameters generated 14
using root node and split node samples instead of the integral difference between 15
empirical copulas is used. To test our hypothesis that VMRF and CMRF will perform 16
better than RF, we considered a drug set with 4 different drugs from CCLE with single 17
common target between them and a drug set with 3 different drugs in GDSC with a 18
common target between them. The CCLE set has 482 cell lines and the GDSC set has 19
308 cell lines. RELIEFF was used to reduce the feature space prior to random forest 20
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application. For simplicity, in this case, we’ve used 30% of the sample cell lines as 21
training data and 70% of them as testing data. 22
The CCLE drugset is SM = { Erlotinib, Lapatinib, ZD6474(Vandetanib) , 23
AZD0530(Saracatinib) } with EGFR as a common target [2–5]. The correlation 24
coefficient of the experimental and predicted response of the testing data are shown in 25
Table B. 26
Table B: Results for CCLE Dataset drug sensitivity prediction for a drugset with 4 drugs in
the form of correlation coefficients for RF , VMRF , CMRF and KBMTL approaches.
Correlation Co-efficients
Drug Set Common Target Drug Name RF VMRF CMRF KBMTL
SM EGFR Erlotinib 0.3533 0.3604 0.3791 0.2576
Lapatinib 0.4142 0.4396 0.4001 0.2682
ZD-6474 0.2067 0.1975 0.1907 0.1583
AZD-0530 0.1419 0.1539 0.1818 0.1120
Table B shows that the average correlation coefficient of these 4 drugs are higher for 27
CMRF (0.2879) and VMRF (0.2878) as compared to RF(0.2790) in spite of RF 28
performing better for couple of these drugs. All three random forest based approaches 29
outperforms KBMTL in terms of correlation coefficients in this scenario. 30
Table C shows the predictive performance for GDSC dataset for a drugset with 3 31
drugs (AZD-0530, Erlotinib, Lapatinib) with common target EGFR. The average 32
correlation coefficient of these 3 drugs is highest in KBMTL (0.5547) followed by CMRF 33
(0.5130), VMRF (0.5116) and RF (0.5053). 34
Table C: Results for GDSC Dataset drug sensitivity prediction for a drugset with 3 drugs in
the form of correlation coefficients for RF , VMRF , CMRF and KBMTL approaches.
Correlation Co-efficients
Drug Set Common Target Drug Name RF VMRF CMRF KBMTL
SM EGFR AZD-0530 0.5869 0.5875 0.5934 0.5555
Erlotinib 0.4755 0.4801 0.5069 0.6615
Lapatinib 0.5316 0.5493 0.5508 0.4470
We have also applied the methodology to the complete dataset consisting of 140 35
drugs in GDSC where joint prediction of 140 drugs is conducted for VMRF, CMRF and 36
KBMTL. The correlation coefficients for 15 of the drugs that are common with CCLE 37
dataset along with the average of all 140 drugs are shown in Table D while Table E 38
shows the performance in terms of NRMSE. In terms of average correlation coefficients, 39
RF performs the best followed by VMRF , CMRF and KBMTL. In terms of 40
NRMSE, the average performance of VMRF and CMRF is similar followed by RF 41
and KBMTL. It appears that for large number of drugs with minimal relationships 42
among the drugs, univariate RF is often the better choice for average performance. 43
Tables F and G shows the performance in the form of correlation coefficients and 44
NRMSE for predicting jointly the 24 drugs in CCLE dataset. Similar to GDSC case 45
scenario, RF performs the best followed by VMRF , CMRF and KBMTL in terms of 46
correlation coefficients. In terms of NRMSE, the average performance of RF is the best 47
followed by KBMTL, VMRF and CMRF. The CCLE dataset also lends support to the 48
conclusion that univariate random forest can outperform the Multivariate approaches 49
when there is limited relationship among the drugs. In terms of time taken for 50
simulation of large set of drugs, VMRF is the fastest followed by RF , CMRF and 51
KBMTL as shown later in Table L. 52
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Table D: Results for GDSC Dataset drug sensitivity prediction for a drugset with 140 drugs in
the form of correlation coefficients is shown (only 15 drugs that are common with CCLE are
shown in detail while the average represents the average of all 140 drugs).
Correlation Coefficients
Drug Set Common Target Drug Name RF VMRF CMRF KBMTL
SM None 17-AAG 0.6209 0.6283 0.5798 0.2446
AZD-0530 0.1132 0.0899 0.0881 0.1297
AZD6244 0.3709 0.3976 0.3520 0.2126
Erlotinib 0.4732 0.3914 0.4096 0.1802
Lapatinib 0.3041 0.3477 0.3865 0.0866
Nilotinib 0.2926 0.2101 0.1936 0.2599
Nutlin-3 0.0482 0.0130 -0.0428 0.2297
Paclitaxel 0.1632 0.1280 0.1561 0.1176
PD-0325901 0.4097 0.4029 0.3351 0.1751
PD-0332991 0.1278 0.0626 0.0850 0.3678
PF2341066 0.2401 0.1472 0.1438 0.1950
PHA-665752 0.1111 0.0096 -0.0034 0.0117
PLX4720 0.1918 0.1718 0.1543 0.0214
Sorafenib 0.0707 0.0185 0.0402 0.0916
TAE-684 0.1323 0.1872 0.0731 0.0661
Average Correlation Coefficient 0.2354 0.2120 0.1985 0.1553
Table E: Results for GDSC Dataset drug sensitivity prediction for a drugset with 140 drugs in
the form of NRMSE is shown (only 15 drugs that are common with CCLE are shown in detail
while the average represents the average of all 140 drugs).
Correlation Co-efficients
Drug Set Common Target Drug Name RF VMRF CMRF KBMTL
SM None 17-AAG 0.8481 0.9223 0.9258 0.9703
AZD-0530 0.9940 0.9965 0.9965 0.9921
AZD6244 0.9602 0.9751 0.9783 0.9787
Erlotinib 0.9280 0.9665 0.9413 0.9842
Lapatinib 0.9589 0.9716 0.9539 1.0009
Nilotinib 0.9913 0.9966 0.9968 0.9901
Nutlin-3 1.0018 1.0016 1.0033 0.9742
Paclitaxel 0.9867 0.9932 0.9897 1.0510
PD-0325901 0.9427 0.9675 0.9770 0.9845
PD-0332991 0.9918 0.9980 0.9969 0.9373
PF2341066 0.9778 0.9922 0.9915 0.9820
PHA-665752 0.9938 1.0013 1.0014 1.0059
PLX4720 0.9877 0.9933 0.9955 1.0047
Sorafenib 0.9977 0.9999 0.9992 0.9977
TAE-684 0.9917 0.9895 0.9974 1.0411
Average Normalized Root Mean Square Error 0.9735 0.9865 0.9865 1.0065
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Table F: Results for CCLE Dataset drug sensitivity prediction for the combined set of 24 drugs
in the form of correlation coefficients.
Correlation Co-efficients
Drug Set Common Target Drug Name RF VMRF CMRF KBMTL
SM None 17-AAG 0.2792 0.2028 0.2606 0.2159
AZD-0530 0.3042 0.3001 0.2708 0.2839
AZD6244 0.4978 0.3637 0.3799 0.5366
Erlotinib 0.3682 0.3206 0.3160 0.3525
Lapatinib 0.3073 0.3059 0.2671 0.2252
Nilotinib 0.5471 0.5581 0.5024 0.4194
Nutlin-3 0.3715 0.3756 0.3921 0.3211
Paclitaxel 0.4342 0.3649 0.4444 0.4475
PD-0325901 0.5671 0.4699 0.4482 0.5782
PD-0332991 0.5136 0.4987 0.4988 0.4329
PF2341066 0.4828 0.4863 0.4559 0.4439
PHA-665752 0.4669 0.4573 0.4254 0.4169
PLX4720 0.3750 0.3724 0.3331 0.1323
Sorafenib 0.5162 0.5073 0.4714 0.4035
TAE-684 0.3972 0.4035 0.3980 0.3904
AEW541 0.4379 0.4236 0.3167 0.3646
Irinotecan 0.6063 0.5921 0.5989 0.6305
L-685458 0.6379 0.6233 0.6286 0.5754
LBW242 0.0740 0.1125 0.0433 0.0951
Panobinostat 0.7073 0.7335 0.6836 0.6472
RAF265 0.2976 0.3177 0.2756 0.2113
TKI258 0.5127 0.4988 0.4912 0.4148
Topotecan 0.6016 0.5876 0.6003 0.6129
ZD-6474 0.3089 0.3274 0.2619 0.2590
Average Correlation Coefficient 0.4422 0.4251 0.4068 0.3921
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Table G: Results for CCLE Dataset drug sensitivity prediction for the combined set of 24 drugs
in the form of Normalized Root Mean Square Error.
NRMSE
Drug Set Common Target Drug Name RF VMRF CMRF KBMTL
SM None 17-AAG 0.9747 0.9854 0.9805 0.9979
AZD-0530 0.9669 0.9724 0.9740 0.9672
AZD6244 0.9274 0.9611 0.9770 0.8526
Erlotinib 0.9404 0.9604 0.9668 0.9405
Lapatinib 0.9520 0.9638 0.9744 0.9777
Nilotinib 0.8980 0.8992 0.9437 0.9204
Nutlin-3 0.9431 0.9476 0.9650 0.9489
Paclitaxel 0.9143 0.9457 0.9533 0.9186
PD-0325901 0.9194 0.9613 0.9779 0.8330
PD-0332991 0.8707 0.8934 0.9394 0.9026
PF2341066 0.9027 0.9140 0.9543 0.9016
PHA-665752 0.8958 0.9085 0.9490 0.9101
PLX4720 0.9432 0.9517 0.9768 0.9964
Sorafenib 0.9010 0.9182 0.9581 0.9162
TAE-684 0.9470 0.9538 0.9797 0.9262
AEW541 0.9440 0.9540 0.9854 0.9337
Irinotecan 0.8373 0.8684 0.9256 0.7763
L-685458 0.8125 0.8412 0.9184 0.8430
LBW242 1.0011 0.9937 0.9995 1.0071
Panobinostat 0.7651 0.7999 0.9039 0.7813
RAF265 0.9589 0.9624 0.9810 0.9910
TKI258 0.8842 0.9085 0.9502 0.9106
Topotecan 0.8410 0.8753 0.9268 0.7919
ZD-6474 0.9556 0.9601 0.9754 0.9749
Average Normalized Root Mean Square Error 0.9124 0.9292 0.9599 0.9134
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Robustness analysis of α (Method-2) using synthetic 53
example 54
At first, we have analyzed robustness of α generated using pareto frontier approach by 55
adding noise to the drug response data and comparing with the α generated from the 56
response without noise. This simulation was conducted using simulated data generated 57
from the same framework mentioned in the synthetic example included in main 58
manuscript. 4 different sets of synthetic data sets were created with different number of 59
samples and corresponding α values are reported for with and without noise added to 60
the drug response (table H). In all cases, we have used 30% of the sample cell lines as 61
training data and 70% of them as testing data. Number of trees were 100 in all cases. 62
Table H: Comparison of α for different sets of synthetic data with and without noise added to
the drug response.
α
Drug Set Number of Samples Without noise With noise
S1 200 6.23 7.63
S2 250 4.53 5.05
S3 300 4.66 5.15
S4 350 4.43 4.95
Finally, we have analyzed the robustness by comparing α generated using different 63
selections of random subsets of the original samples. Table I shows the α values 64
generated from a drugset with N=350 samples and with random subset of the same 65
data with 0.9N , 0.8N , 0.7N samples. 66
Table I: Comparison of αs for different selections of random subsets of the original samples in
a specific synthetic dataset. Original number of samples were 350 in this particular example.





Simulation Time Complexity 67
Simulation time of drugsets SC1, SC2 and SC3 of GDSC are reported in Table J for RF, 68
VMRF and CMRF methods. The reported simulation times are the time needed to 69
generate complete result for all drugs in a drug set for 5 fold cross validation. 70
Simulation was conducted in a Intel Core i7 computer with 16GB RAM. 4 labs had 71
been used while running the simulation under MATLABPOOL. 72
Table J: Simulation time for different drugsets in GDSC data. The reported simulation times
are the time needed to generate complete result for all drugs in a drug set for 5 fold cross
validation.
Simulation Time (seconds)
Drug Set Number of Samples RF VMRF CMRF (Empirical)
SC1 316 982 613 13850
SC2 349 1110 690 15400
SC3 645 2192 1282 28764
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In addition to 5-fold cross validation simulation times, we are reporting the 73
simulation times with 30% of the sample cell lines as training data and 70% of them as 74
testing data in Table K . We are also including the CMRF (parametric) simulation time 75
in table K . Table L shows the simulation times for predicting all drugs jointly for 76
GDSC and CCLE datasets using RF, VMRF, CMRF (parameteric) and KBMTL 77
approaches. Similar to Table K, we have used 30% of the cell lines as training data and 78
70% of them as testing data. 79
Table K: Simulation time for different drugsets in GDSC data. The reported simulation times
are the time needed to generate complete result for all drugs in a drug set for 30-70 case.
Simulation Time (seconds)
Drug Set Number of Samples RF VMRF CMRF (Empirical) CMRF (Parametric)
SC1 316 169 90 734 412
SC2 349 190 105 795 455
SC3 645 350 190 1510 850
Table L: Simulation time for different methods for all drugs of GDSC dataset (140) and CCLE dataset (24). The reported simulation
times are the time (in seconds) needed to generate complete result for all drugs for 30-70 case.
Method Name GDSC dataset CCLE dataset
Random Forest 3,930 833.47
Multivariate Random Forest 51.17 45.70
Parametric CMRF 21,700 1,230
KBMTL 192,000 46,400
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